US 7,256,184 B2Granted

Treatment of aging disorders in humans

OwnerVictorio C. Rodriguezinventor

Life of this patent

Estimating the term…

Loading patent…

Abstract

A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes. Such conditions include chronic neurodegenerative conditions including dementia such as Alzheimer's disease. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of a compound that increases the presence of one or more cell-specific carbonic anhydrase enzymes whose levels are reduced in the patient. Such compound may be the cell-specific carbonic anhydrase enzyme, a compound that when absorbed by the body reacts or dissociates to form the cell-specific carbonic anhydrase enzyme, or a compound that promotes the natural generation of the cell-specific carbonic anhydrase enzyme within the body.

Claims15

Dependent claims

A method for the treatment of a condition of aging in a human patient comprising:

(a) assaying for a decrease in the level of one or more carbonic anhydrase isozymes in a tissue of a human patient suspected of having a condition of aging selected from the group consisting of dementia, neurodegenerative disease, Alzheimer's disease and combinations thereof;
(b) selecting the human patient whose assay shows a decrease in the level of one or more carbonic anhydrase isozymes;
and
(c) administering to the selected patient a pharmaceutically effective amount of 1,25-dihydroxyvitamin D3 to increase the level of one or more carbonic anhydrase isozymes that are present at decreased levels in the patient;
wherein the patient has reduced symptoms and signs of dementia, neurodegenerative disease, Alzheimer's disease or a combination thereof after being administered the pharmaceutically effective amount of 1,25-dihydroxyvitamin D3.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/858,091Filed 1 Jun 2004 · continuation in part
Priority: 16 Oct 2000
Published: US 2004/0253223 A116 Dec 2004
Granted: 14 Aug 2007
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 33/30
Heavy metals; Compounds thereof: zinc; Compounds thereof
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 38/51
Enzymes; Proenzymes; Derivatives thereof: lyases
A61P 25/00
Drugs for disorders of the nervous system

Family

Application09/688,290Parent of this continuation-in-part · filed 16 Oct 2000
Application10/077,719Parent of this continuation-in-part · filed 15 Feb 2002
US 2004/0253223 A1Pre-grant publication · published 16 Dec 2004
US 6,821,997 B1Parent of this continuation-in-part
US 7,256,184 B2This patent

From the US filing history. Foreign family members aren’t listed.